Common Contracts
14 similar Employment Agreement contracts by Rubius Therapeutics, Inc.
EMPLOYMENT AGREEMENTEmployment Agreement • July 29th, 2021 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 26th day of July, 2021 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Dannielle Appelhans (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 28th, 2020 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 23rd day of September, 2020 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Jose Carmona (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2020 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 20th day of December, 2019 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Christina Marie Coughlin, M.D., Ph.D. (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 11th, 2020 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 4th day of January, 2020 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Laurence A. Turka, M.D., (the “Executive”).
EX-10.7 7 a2236172zex-10_7.htm EX-10.7 EMPLOYMENT AGREEMENTEmployment Agreement • May 5th, 2020 • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 2nd day of July, 2018 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Torben Straight Nissen, Ph.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 12th, 2020 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 7th day of October, 2019 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Maiken Keson-Brookes (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 9th, 2018 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 2nd day of July, 2018 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Pablo Cagnoni, M.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 9th, 2018 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 2nd day of July, 2018 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Torben Straight Nissen, Ph.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 9th, 2018 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 29th day of June, 2018 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew Oh (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 9th, 2018 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 29th day of June, 2018 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Christopher L. Carpenter, M.D., Ph.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 2nd, 2018 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the day of , 2018 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Torben Straight Nissen, Ph.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 2nd, 2018 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the day of , 2018 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew Oh (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 2nd, 2018 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the day of , 2018 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Pablo Cagnoni, M.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 2nd, 2018 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the day of , 2018 between Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), and Christopher L. Carpenter, M.D., Ph.D. (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
